Arzneimittelinteraktionen bei der Antiparkinson-Therapie

Zusammenfassung

Parkinson-Patienten müssen häufig gleichzeitig mit Medikamenten gegen weitere Erkrankungen behandelt werden. Das Interaktionsrisiko ist dabei hoch und kann lebensbedrohlich sein. Mögliche Interaktionen können häufig auch bei guten pharmakologischen Kenntnissen nicht vorhergesagt werden, sondern müssen in Review-Artikeln oder Datenbanken nachgeschlagen werden. Abgehandelt werden die relevanten Interaktionen aller Antiparkinsonmittel untereinander, ferner solche mit Psychopharmaka, gastrointestinalen Therapeutika, Herz-Kreislauf-Mitteln, Nahrungsbestandteilen, Vitaminen, Eisensalzen, Mitteln bei Blutgerinnungsstörungen, Narkotika und Analgetika. Tabellen helfen bei der Schnellsuche. Wichtige Empfehlungen für den Alltag in Klinik und Praxis werden gegeben, um so die Arzneimittelsicherheit zu erhöhen.

Summary

Patients with parkinson symptoms are often co-medicated with drugs against additional diseases. Combination therapies may induce drug interactions including lifethreatening events. Drug interactions cannot be anticipated on the basis of having a good pharmacological background but have to be confirmed using reviews or data banks. The relevant interactions of all antiparkinsonian drugs with themselves, with psychopharmacological drugs, drugs used for gastrointestinal and cardiology complaints, with food, vitamins and iron salts, with drugs influencing bleeding, with narcotics and analgetics are described and listed. Hints to react on or correct the interactions are given. Thus drug safety would be increased.

Schlüsselwörter

Antiparkinson-Medikamente - Parkinson-Krankheit - Arzneimittelinteraktionen

Keywords

Antiparkinsonian agents - Parkinson’s disease - drug interactions

• Literatur

• 1 Pfeiffer RE. Antiparkinsonian agents. Drug interactions of clinical significance. Drug Safety 1996; 14: 343-54.
• 2 Cluff LE, Petrie JC. Clinical effects of interaction between drugs. Excerpta Medica. Amsterdam. 1974
• 3 Kuzuhara S. Drug-induced psychotic symptoms in Parkinson’s disease. Problems, management and dilemma. J Neurol 2001; 248 (Suppl. 03) III 28-31.
• 4 Hanzal F. Treatment of Parkinson’s syndrome with L-dopa and L-carbidopa. Munch Med Wochenschr 1976; 118: 653-6.
• 5 Saller R, Berger Th, Ulmer E, Hellenbrecht M. Praktische Pharmakologie. 2nd Edition.. Stuttgart: Schattauer; 1983
• 6 Schwarz J. Morbus Parkinson. In: Lehmann-Horn F, Ludolph AC. (eds). Neurologische Therapie. München: Urban & Fischer; 2000
• 7 Skiric P, Geber J, Ivanovic D, Suchanek E, Gjuris V, Tucan-Foretic M, Mise S, Cvitanovic B, Rotkvic I. Dopamine antagonists induce gastric lesions in rats. Eur J Pharmacol 1986; 131: 105-9.
• 8 Jost WH. Therapie des idiopathischen Parkinson-Syndroms. 2nd.. Bremen: Edition Uni-med Verlag.;
• 9 Dalvi A, Ford B. Antiparkinsonian Agents. Clinically significant drug interactions and adverse effects, and their management. CNS Drugs 1995; 09: 291-310.
• 10 Bozek CB, Suchowersky O, Purves S, Calne S, Calne DB. Sinemet in Parkinson’s disease: efficacy with and without food. Clin Neuropharmacol 1986; 09: 196-9.
• 11 Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E, Martinelli P. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37.
• 12 Dingemanse J, Kleinbloesem CH, Crevoisier Ch, Lankhaar G, Gasser UE. Pharmacokinetic studies with a dual-release formulation of Levodopa, a novel principle in the treatment of parkinson’s disease. Eur Neurol 1998; 39: 119-24.
• 13 Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991; 31: 413-7.
• 14 Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of the meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled is release in parkinsonian patients. Eur J Clin Pharmacol 1998; 54: 303-8.
• 15 Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989; 39 (Suppl. 02) 25-38.
• 16 Caranasos GJ, Stewart RB. Clinically desirabele drug interactions. Ann Rec Toxicol 1985; 25: 67-95.
• 17 Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-Dopa in Parkinson`s disease: a pilot study. Clin Pharmacol 2001; 24: 208-13.
• 18 Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with parkinsons disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505.
• 19 Quinn N, Illas A, Lhermitte F, Agid Y. Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 1981; 31: 662-7.
• 20 Jost WH, Brück C. Drug Interactions in the treatment of Parkinson`s disease. J Neurol. 2002. 249: III 24-29.
• 21 Kulig K, Moore LL, Kirk M, Smith D, Stallworth J, Rumack B. Bromocriptine-associated headache: possible life-threatening sympathomimetic interaction. Obstet Gynecol 1991; 78: 941-3.
• 22 Martignoni E, Pacchetti C, Godi L, Rainer E, Horowski R, Nappi G. Treatment of »de novo« PD patients with lisuride and L-deprenyl combines: A long term study. New Trends Clin Neuropharmacol 1992; 06: 53-7.
• 23 Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE, Chase TN. Continuous lisuride effects on central dopaminergic mechanism in Parkinson’s disease. Ann Neurol 1992; 32: 776-81.
• 24 Brefel C, Thalamus C, Rayet S, Lopez-Gil A, Fitzpatrick K, Bullman S, Citerone DR, Taylor AC, Monastruc JL, Rascol O. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998; 45: 412-5.
• 25 Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF. Identification of drugs inhibiting the in vitro metabolism of tacrolismus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-90.
• 26 Alegre M, Noe E, Martinez JMLage. Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease (Letter). Neurologia 1997; 12: 429.
• 27 Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinsons’s disease. Eur J Clin Pharmacol 1999; 55: 299-303.
• 28 Brecht HM. Dopaminagonisten im Vergleich. Aktuelle Neurologie 1998; 25: S310-16.
• 29 Taylor AC, Beerahee A, Citerone DR, Cyronak MJ, Leigh TJ, Fitzpatrick KL, Lopez-Gil A, Vakil SD, Burns E, Lenox G. Lack of a pharma-cokinetic interaction at steady state between ropinirole and L-dopa in patients with parkinson`s disease. Pharmacotherapy 1999; 19: 150-6.
• 30 Minea D, Varga I, Falup-Pecurariu C, de Mey C, Retzow A, Althaus M. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson´s disease. Clin Neuropharmacol 2001; 24: 235-8.
• 31 Nicholson G, Pereira AC, Hall GM. Parkinson’s disease and anaesthesia. Br J Anaesth 2002; 89: 904-16.
• 32 Reichmann H. Selegiline (L-Deprenyl). Aktuelle Neurologie 1998; 25: 322-3.
• 33 Dingemanse J, Kneer J, Wallnofer A, Kettler R, Zurcher G, Koulu M, Korn A. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996; 19: 399-414.
• 34 Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teravainen H. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson`s disease. Mov Disord 1997; 12: 497-505.
• 35 Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol 1995; 42: 95-9.
• 36 Heikkinen H, Nutt JG, LeWitt PA, Kollar WC, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to LDopa in Parkinson`s disease. Clin Neuropharmacol 2001; 24: 150-7.
• 37 Illi A, Sundberg S, Ojala PKarlsson, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996; 51: 273-6.
• 38 Renfrew C, Dickson R, Schwab C. Severe hypertension following ephedrine administration in a patient receiving entacapone. Anesthesiology 2000; 93: 1562.
• 39 Jorga KM, Potteler B, Modi M, Rabbia M. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine. Eur Neurol 2000; 44: 94-103.
• 40 Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002; 53: 485-91.
• 41 Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: Significance in treatment of Parkinson’s disease. Drugs 1973; 06: 364-88.
• 42 Verspohl EJ. In: Ammon HPT: Arzneimittelneben-und -wechselwirkungen 4. Auflage Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2001: 503-24.
• 43 ABDA-Datenbank, Grosse Deutsche Spezialitätentaxe. Lauer-Taxe plus. Pharma Daig + Lauer GmbH, Fürth, Fischer Software GmbH, Stuttgart..
• 44 Beizer JL. Treatment options in parkisnon’s disease. American Pharmacy 1995; 01: 20-32.